Area of research
Radiology, Nuclear Medicine and Imaging · Pulmonary and Respiratory Medicine
Research interest
Research interests include Radiopharmaceutical Chemistry and Applications, Prostate Cancer Treatment and Research, Medical Imaging Techniques and Applications, and Monoclonal and Polyclonal Antibodies Research.
Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study
Deescalated<sup>225</sup>Ac-PSMA-617 Versus<sup>177</sup>Lu/<sup>225</sup>Ac-PSMA-617 Cocktail Therapy: A Single-Center Retrospective Analysis of 233 Patients
Production of innovative radionuclides for medical applications at the CERN-MEDICIS facility
Data from Preclinical Evaluation of <sup>225</sup>Ac-Labeled Single-Domain Antibody for the Treatment of HER2<sup>pos</sup> Cancer
Supplementary Data from Preclinical Evaluation of <sup>225</sup>Ac-Labeled Single-Domain Antibody for the Treatment of HER2<sup>pos</sup> Cancer
Supplementary Data from Preclinical Evaluation of <sup>225</sup>Ac-Labeled Single-Domain Antibody for the Treatment of HER2<sup>pos</sup> Cancer
Data from Preclinical Evaluation of <sup>225</sup>Ac-Labeled Single-Domain Antibody for the Treatment of HER2<sup>pos</sup> Cancer
Preclinical Evaluation of 225Ac-Labeled Single-Domain Antibody for the Treatment of HER2pos Cancer.
Production and Supply of α-Particle–Emitting Radionuclides for Targeted α-Therapy
Dosing 225Ac-DOTATOC in patients with somatostatin-receptor-positive solid tumors: 5-year follow-up of hematological and renal toxicity
CERN-MEDICIS: A Review Since Commissioning in 2017
Radiochemical separation of 224Ra from 232U and 228Th sources for 224Ra/212Pb/212Bi generator
Diverse metabolic response of cancer cells treated with a 213Bi-anti-EGFR-immunoconjugate
Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA
Therapeutic Efficacy of <sup>213</sup>Bi-labeled sdAbs in a Preclinical Model of Ovarian Cancer
First patient exceeding 5-year complete remission after 225Ac-PSMA-TAT
Patients Resistant Against PSMA-Targeting α-Radiation Therapy Often Harbor Mutations in DNA Damage-Repair–Associated Genes
DNA damage in human whole blood caused by radiopharmaceuticals evaluated by the comet assay
Assessment of 213Bi-anti-EGFR MAb treatment efficacy in malignant cancer cells with [1-13C]pyruvate and [18F]FDG
Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with <sup>225</sup>Ac-PSMA-617: Swimmer-Plot Analysis Suggests Efficacy Regarding Duration of Tumor Control
An Overview of Targeted Alpha Therapy with <sup>225</sup>Actinium and <sup>213</sup>Bismuth
Initial clinical experience performing sialendoscopy for salivary gland protection in patients undergoing 225Ac-PSMA-617 RLT
Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with <sup>225</sup>Ac-PSMA-617: Dosimetry Estimate and Empiric Dose Finding
Targeted alpha therapy of mCRPC: Dosimetry estimate of 213Bismuth-PSMA-617
<sup>225</sup>Ac-PSMA-617 for PSMA-Targeted α-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer
213Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience
DNA Double Strand Breaks as Predictor of Efficacy of the Alpha-Particle Emitter Ac-225 and the Electron Emitter Lu-177 for Somatostatin Receptor Targeted Radiotherapy
213Bi-anti-EGFR radioimmunoconjugates and X-ray irradiation trigger different cell death pathways in squamous cell carcinoma cells